WO2007078806A2 - Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine - Google Patents

Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine Download PDF

Info

Publication number
WO2007078806A2
WO2007078806A2 PCT/US2006/047652 US2006047652W WO2007078806A2 WO 2007078806 A2 WO2007078806 A2 WO 2007078806A2 US 2006047652 W US2006047652 W US 2006047652W WO 2007078806 A2 WO2007078806 A2 WO 2007078806A2
Authority
WO
WIPO (PCT)
Prior art keywords
plasma
choline
phosphatidylcholine
hydrogen peroxide
tissue
Prior art date
Application number
PCT/US2006/047652
Other languages
French (fr)
Other versions
WO2007078806A3 (en
Inventor
Xian-Cheng Jiang
Mohammad Reza Hojjati
Original Assignee
The Research Foundation Of State University Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Research Foundation Of State University Of New York filed Critical The Research Foundation Of State University Of New York
Priority to EP06847636A priority Critical patent/EP1960534A4/en
Priority to JP2008545793A priority patent/JP2009519713A/en
Priority to AU2006333135A priority patent/AU2006333135A1/en
Priority to US12/097,380 priority patent/US20090148877A1/en
Priority to CA002634042A priority patent/CA2634042A1/en
Publication of WO2007078806A2 publication Critical patent/WO2007078806A2/en
Publication of WO2007078806A3 publication Critical patent/WO2007078806A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2326/00—Chromogens for determinations of oxidoreductase enzymes
    • C12Q2326/90—Developer
    • C12Q2326/96—4-Amino-antipyrine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids

Definitions

  • lipoproteins also contain phospholipids, among them phosphatidylcholine (PC) and sphingomyelin (SM) are two major ones, the former comprising about 70% and laTter about 20% of total phospholipids.
  • PC phosphatidylcholine
  • SM sphingomyelin
  • both plasma SM and SM/PC ratio are independent risk factors for coronary heart disease. It has been known for some time that SM accumulates in atheromas in human and animal models. Low density lipoprotein (LDL) extracted from human atherosclerotic lesions is much richer in SM than LDL from plasma.
  • LDL low density lipoprotein
  • Plasma SM levels in apoE knockout (apoE KO) mice are 4-fold higher than in wild type mice, and this may partly explain the increased atherosclerosis in these animals.
  • the SM/PC ratio was 5-fold higher in VLDL from hypercholesterolemic rabbits.
  • the invention relates to a method for measuring plasma and tissue sphingomyelin and phosphatidylcholine comprising 1) catalyzing the hydrolysis of sphingomylelin to phosphoryl choline and n-acylsphingosine with bacterial SMase; 2) generating choline from phosphorylcholine produced from step 1) with alkaline phosphatase; 3) generating hydrogen peroxide by adding choline oxidase; and 4) adding hydrogen peroxide and with DAOS (N-Ethyl-N-(2-hydroxy-3-sulfopropyl)- 3,5-dimethoxyaniline, sodium salt), 4-aminoantipyrine and peroxidase, to generate a blue to purple dye, preferably with an optimal absorption at 595 nm.
  • DAOS N-Ethyl-N-(2-hydroxy-3-sulfopropyl)- 3,5-dimethoxyaniline, sodium salt
  • the method comprises 1) catalyzing the hydrolysis of phosphatidiycholine to choline and phosphatidic acid with bacterial phospholipase D; 2) generating hydrogen peroxide by adding choline oxidase; and 3) adding hydrogen peroxide and with DAOS (N-Ethyl-N-(2-hydroxy-3- sulfopropyl)-3,5-dimethoxyaniline, sodium salt), 4-aminoantipyrine and peroxidase, to generate a blue to purple dye, preferably with an optimal absorption at 595 nm.
  • DAOS N-Ethyl-N-(2-hydroxy-3- sulfopropyl)-3,5-dimethoxyaniline, sodium salt
  • both phosphatidlycholine and sphingomylelin are measured concurrently by combining the two methods described above.
  • SM and PC were measured by four steps : 1) lipid extraction; 2) thin layer chromatograph (TLC); 3) SM and PC extraction from corresponding spots on the TLC plate, and 4) quantification of phosphate in each extraction.
  • the whole procedure is time-consuming and not sensitive.
  • PC + SM total choline-containing phospholipids
  • the invention relates to two rapid, specific and sensitive assays for plasma SM and PC measurements.
  • the invention relates to two rapid, specific and sensitive enzymatic measurements for both Sphingomyelin (SM) and phosphatidylcholine (PC).
  • SM Sphingomyelin
  • PC phosphatidylcholine
  • Their concentration is classically measured by lipid extraction, thin layer chromatograph, and phosphate determination on separated SM or PC spots.
  • plasma is incubated with bacterial sphingomyelinase (for SM measurement) or bacterial phospholipase D (for PC measurement), alkaline phosphatase, choline oxidase, peroxidase, N-Ethyl-N-(2- hydroxy-3-sulfopropy])-3,5-dimethoxyaniline, and 4-aminoantipyrine, preferably for about 45 minutes.
  • a blue dye with an optimal absorption at 595 nm, is generated.
  • PC levels do not influence SM measurement or vice versa.
  • the linear range for the SM measurement is about 0.5 to about 5 ⁇ g and for PC was about 2.5 to about 20 ⁇ g.
  • the inter-assay coefficient of variation of the assay was about 1.7+0.05% for SM and 3.1 ⁇ 0.13% for PC.
  • phospholipase D might contaminate with SMase activity or vice versa.
  • phospholipase D from BIOMOL International is used in the inventive method or assay.
  • the terms "assay” and “method” have the same meaning herein and are used interchangeably herein.
  • SMase available in Sigma-Aldrich can be used in the inventive method, preferably S-8889. All alkaline phosphatase, choline oxidase, and peroxidase available in Sigma-Aldrich can be used on in all of the methods of the invention.
  • some reagents can be chosen. For instance, phenol can be used to generate a red quinine pigment, with an optimal absorption at 505 nm and TOOS (3-(N-ethyl-3-methylanilino)-2-hydroxypropanesulfonic acid) can be used to generate a purple pigment, with an optimal absorption at 550 nm.
  • TOOS 3-(N-ethyl-3-methylanilino)-2-hydroxypropanesulfonic acid
  • hemolytic plasma could significantly influence the absorption at both wave lengths. Utilizing DAOS could sufficiently avoid the effect of hemolysis (Fig.4).
  • novel methods for plasma SM and PC measurement described herein are simple, rapid, specific, sensitive and has high- throughput. They are suitable for larger scale clinical samples measurements or drug screening and may be adaptive for tissue SM and PC measurements.
  • SMase alkaline phosphatase, choline oxidase, peroxidase and 4- aminoantipyrine as well as standard SM and standard PC were purchased from Sigma-AIdrich.
  • Phospholipase D was purchased from BIOMOL International.
  • DAOS N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline, sodium salt was purchased from Dojindo Molecular Technologies, Inc.
  • SM measurement There were four steps for enzymatic measurement of plasma SM levels (Fig. IA): 1) Bacterial SMase hydrolyzed SM to phosphorylcholine and «-acylsphingosine; 2) alkaline phosphatase generated choline from phosphorylcholine; 3) choline was used to generate hydrogen peroxide in a reaction catalyzed by choline oxidase; and 4) hydrogen peroxide was used together with DAOS (N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline, sodium salt), 4-aminoantipyrine and peroxidase, as a catalyst, to generate a blue to purple dye, with an optimal absorption at 595 run.
  • DAOS N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline, sodium salt
  • the reaction buffer was Tris- HCl 0.05 M with calcium chloride 5 mg/dl, pH 8.
  • Enzymes concentrations in a 50 ml reaction buffer were as follows: SMase 25U, alkaline phosphatase 500U, choline oxidase 25U, and peroxidase 100OU.
  • DAOS concentration was 0.73mM and 4-aminoantipyrine concentration was 0.73 mM.
  • Five ⁇ l of plasma were added to 100 ⁇ l reaction buffer plus enzymes and after 45 minutes incubation at 37 0 C, the absorption was measured at 595 run on a spectrophotometric plate reader.
  • Standard SM solution (50 mg/dl) preparation 5 mg of SM was dissolved in 10 ml 2% Triton X-100 ethanol solution.
  • PC measurement There were three steps for enzymatic measurement of plasma PC levels (Fig 2B): 1) Bacterial phospholipase D (specific for PC, no reaction with SM) hydrolyzed PC to choline and phosphatidic acid; 2) choline was used to generate hydrogen peroxide in a reaction catalyzed by choline oxidase; 3) hydrogen peroxide was used together with DAOS (N-Ethyl-N-(2-hydroxy-3- sulfopropyl)-3,5-dimethoxyaniline, sodium salt), 4-aminoantipyrine and Peroxidase, as a catalyst, to generate a blue to purple dye, with an optimal absorption at 595 nm.
  • DAOS N-Ethyl-N-(2-hydroxy-3- sulfopropyl)-3,5-dimethoxyaniline, sodium salt
  • 4-aminoantipyrine and Peroxidase as a catalyst, to generate a blue to purple dye, with
  • the reaction buffer was Tris-HCL 0.05 M with calcium chloride 5 mg/dl, pH 7.
  • Enzymes concentrations in a 50 ml reaction buffer were as follows: Phospholipase D 6000U (added at the time of measurement), Choline oxidase 25U, Peroxidase 100OU.
  • DAOS concentration was O.73mM and 4- aminoantipyrine concentration was 0.73 mM.
  • Five ⁇ l of plasma were added to 100 ⁇ l reaction buffer plus enzymes and after 45 minutes incubation at 37 0 C, the absorption was measured at 595 nm.
  • Standard SM solution (100 mg/dl) preparation 10 mg of PC was dissolved in 10 ml 2% Triton X-100 ethanol solution.
  • Total phospholipids measurement The total choline-containing phospholipids (PC + SM) in plasma was measured by an enzymatic method (Wako Pure Chemical)
  • SM or PC levels were carried out by using novel 4- or 3 -step procedure (Fig.l). As indicated in Fig 2, the linear range for the SM measurement was 0.5 to 5 ⁇ g and for PC was 2.5 to 20 ⁇ g (Fig.2). SM and PC concentration were measured in different amount of pooled plasma and found that the linear range for both assays was 2.5 ⁇ l to 10 ⁇ l (Fig.3).
  • SM + PC total choline-containing phosphlipid
  • DAOS was instead of phenol in the last step of the reaction with the highest absorption at 595 nm. This change not only increases the sensitivity of the method (less than 10 mg/dl of SM can be detected) but also avoids the effect of hemolysis.
  • Standard curve for the SM and PC measurements Standard curve with the standard SM (0.35 to 3.5 ⁇ g) was linear for the SM measurement method. Standard curve with the standard PC (6 to 24 ⁇ g) was linear for the PC measurement method. The linear range of plasma SM in the assay was between 10 and 120 mg/dl. The linear range of plasma PC in the assay was between 10 and 250 mg/dl.
  • Fig. 1 Strategy for SM and PC measurements.
  • Fig. 3 Linear range of plasma SM and PC measurements. Pooled mouse plasma was used. Different amount of the plasma supplemented with saline to 20 ⁇ l was incubated with 100 ⁇ l of reaction buffer at 37 0 C for 45 min, the absorption was measured at 595 nm. A. Plasma linear range for SM measurement .B. Plasma linear range for PC measurement.
  • Fig. 4 Specificity of the SM and PC measurements. A. Different concentration of PC was used in the SM method; B. Different concentration of SM was used in the PC method.
  • Fig. 5 The effect of hemolysis on OD reading at 595 nm.
  • Ten ⁇ l of low, medium and high hemolytic plasma samples are incubated with 100 ⁇ l of SM assay solution but without SMase at 37 0 C for 45 min, and their absorption was measured at 595 nm.
  • BKG Background; LOW: Low hemolysis; MED: Medium hemolysis;

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A method for measuring sphingomyelin and phosphatidylcholine comprising incubating sphingomyelin and phosphatidylcholine with bacterial sphingomyelinase and bacterial phospholipase D, alkaline phosphatase, choline oxidase, peroxidase, N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline, and 4-aminoantipyrine, preferably for about 45 minutes. A blue dye is generated.

Description

ENZYMATIC METHODS FOR MEASURING PLASMA AND TISSUE SPHINGOMYLELIN AND PHOSPHATIDYLCHOLINE
BACKGROUND OF THE INVENTION Besides cholesterol and triglycerides, lipoproteins also contain phospholipids, among them phosphatidylcholine (PC) and sphingomyelin (SM) are two major ones, the former comprising about 70% and laTter about 20% of total phospholipids. In a human case-control study, it was indicated that both plasma SM and SM/PC ratio are independent risk factors for coronary heart disease. It has been known for some time that SM accumulates in atheromas in human and animal models. Low density lipoprotein (LDL) extracted from human atherosclerotic lesions is much richer in SM than LDL from plasma. Plasma SM levels in apoE knockout (apoE KO) mice are 4-fold higher than in wild type mice, and this may partly explain the increased atherosclerosis in these animals. The SM/PC ratio was 5-fold higher in VLDL from hypercholesterolemic rabbits.
Recently, it has been demonstrated that administration of myriocin (an inhibitor of SM synthesis) into apoE KO mice dramatically decrease SM, increases PC and thus decreases SM/PC ratio in the plasma, and significantly decreased the atherosclerotic lesion area. These data suggest that SM might play a promoting role, while PC might play a preventive role, in the development of atherosclerosis. Their measurements might provide new insights into atherogenesis in humans and in various mouse models as well.
Although the importance of both phospholipids is very obvious, there are no simple, rapid, sensitive and high-throughput methods for their measurements. Classically, plasma SM and PC were measured by lipid extraction, thin layer chromatograph, and phosphate determination on separated SM or PC spots. This method is time-consuming and not sensitive.
Accordingly, there is a need for new methods of measuring SM and PC. SUMMARY OF THE INVENTION
The invention relates to a method for measuring plasma and tissue sphingomyelin and phosphatidylcholine comprising 1) catalyzing the hydrolysis of sphingomylelin to phosphoryl choline and n-acylsphingosine with bacterial SMase; 2) generating choline from phosphorylcholine produced from step 1) with alkaline phosphatase; 3) generating hydrogen peroxide by adding choline oxidase; and 4) adding hydrogen peroxide and with DAOS (N-Ethyl-N-(2-hydroxy-3-sulfopropyl)- 3,5-dimethoxyaniline, sodium salt), 4-aminoantipyrine and peroxidase, to generate a blue to purple dye, preferably with an optimal absorption at 595 nm. In another embodiment, the method comprises 1) catalyzing the hydrolysis of phosphatidiycholine to choline and phosphatidic acid with bacterial phospholipase D; 2) generating hydrogen peroxide by adding choline oxidase; and 3) adding hydrogen peroxide and with DAOS (N-Ethyl-N-(2-hydroxy-3- sulfopropyl)-3,5-dimethoxyaniline, sodium salt), 4-aminoantipyrine and peroxidase, to generate a blue to purple dye, preferably with an optimal absorption at 595 nm.
In another embodiment, both phosphatidlycholine and sphingomylelin are measured concurrently by combining the two methods described above.
DETAILED DESCRIPTION OF THE INVENTION DISCUSSION
Classically, SM and PC were measured by four steps : 1) lipid extraction; 2) thin layer chromatograph (TLC); 3) SM and PC extraction from corresponding spots on the TLC plate, and 4) quantification of phosphate in each extraction. The whole procedure is time-consuming and not sensitive. Although there is a simple method for measuring total choline-containing phospholipids (PC + SM) (Wako Pure Chemical), there is no corresponding method for direct SM and PC measurements. The invention relates to two rapid, specific and sensitive assays for plasma SM and PC measurements.
The invention relates to two rapid, specific and sensitive enzymatic measurements for both Sphingomyelin (SM) and phosphatidylcholine (PC). (SM) and (PC) are two major phospholipids on plasma lipoproteins. Their concentration is classically measured by lipid extraction, thin layer chromatograph, and phosphate determination on separated SM or PC spots.
In the inventive method, plasma is incubated with bacterial sphingomyelinase (for SM measurement) or bacterial phospholipase D (for PC measurement), alkaline phosphatase, choline oxidase, peroxidase, N-Ethyl-N-(2- hydroxy-3-sulfopropy])-3,5-dimethoxyaniline, and 4-aminoantipyrine, preferably for about 45 minutes. A blue dye, with an optimal absorption at 595 nm, is generated.
PC levels do not influence SM measurement or vice versa. The linear range for the SM measurement is about 0.5 to about 5 μg and for PC was about 2.5 to about 20 μg. The inter-assay coefficient of variation of the assay was about 1.7+0.05% for SM and 3.1 ± 0.13% for PC. These two methods are amenable to automation and can be adopted for large-scale, high-throughput assays. Using SMase and phospholipaes D render the specificity of our assays.
However, not all the commercial available enzymes are usefule. Some of phospholipase D might contaminate with SMase activity or vice versa. Preferably phospholipase D from BIOMOL International is used in the inventive method or assay. The terms "assay" and "method" have the same meaning herein and are used interchangeably herein.
SMase available in Sigma-Aldrich can be used in the inventive method, preferably S-8889. All alkaline phosphatase, choline oxidase, and peroxidase available in Sigma-Aldrich can be used on in all of the methods of the invention. In the last step of the inventive method, i.e. converting H2O2 into a readable compound, some reagents can be chosen. For instance, phenol can be used to generate a red quinine pigment, with an optimal absorption at 505 nm and TOOS (3-(N-ethyl-3-methylanilino)-2-hydroxypropanesulfonic acid) can be used to generate a purple pigment, with an optimal absorption at 550 nm. However, hemolytic plasma could significantly influence the absorption at both wave lengths. Utilizing DAOS could sufficiently avoid the effect of hemolysis (Fig.4).
The novel methods for plasma SM and PC measurement described herein are simple, rapid, specific, sensitive and has high- throughput. They are suitable for larger scale clinical samples measurements or drug screening and may be adaptive for tissue SM and PC measurements.
With the aim to better illustrate the present invention, without posing any limitation to it, the following examples are now given.
MATERIALS AND METHODS
Reagents: SMase, alkaline phosphatase, choline oxidase, peroxidase and 4- aminoantipyrine as well as standard SM and standard PC were purchased from Sigma-AIdrich. Phospholipase D was purchased from BIOMOL International. DAOS (N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline, sodium salt) was purchased from Dojindo Molecular Technologies, Inc.
SM measurement: There were four steps for enzymatic measurement of plasma SM levels (Fig. IA): 1) Bacterial SMase hydrolyzed SM to phosphorylcholine and «-acylsphingosine; 2) alkaline phosphatase generated choline from phosphorylcholine; 3) choline was used to generate hydrogen peroxide in a reaction catalyzed by choline oxidase; and 4) hydrogen peroxide was used together with DAOS (N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline, sodium salt), 4-aminoantipyrine and peroxidase, as a catalyst, to generate a blue to purple dye, with an optimal absorption at 595 run. The reaction buffer was Tris- HCl 0.05 M with calcium chloride 5 mg/dl, pH 8. Enzymes concentrations in a 50 ml reaction buffer were as follows: SMase 25U, alkaline phosphatase 500U, choline oxidase 25U, and peroxidase 100OU. DAOS concentration was 0.73mM and 4-aminoantipyrine concentration was 0.73 mM. Five μl of plasma were added to 100 μl reaction buffer plus enzymes and after 45 minutes incubation at 37 0C, the absorption was measured at 595 run on a spectrophotometric plate reader. Standard SM solution (50 mg/dl) preparation: 5 mg of SM was dissolved in 10 ml 2% Triton X-100 ethanol solution.
PC measurement: There were three steps for enzymatic measurement of plasma PC levels (Fig 2B): 1) Bacterial phospholipase D (specific for PC, no reaction with SM) hydrolyzed PC to choline and phosphatidic acid; 2) choline was used to generate hydrogen peroxide in a reaction catalyzed by choline oxidase; 3) hydrogen peroxide was used together with DAOS (N-Ethyl-N-(2-hydroxy-3- sulfopropyl)-3,5-dimethoxyaniline, sodium salt), 4-aminoantipyrine and Peroxidase, as a catalyst, to generate a blue to purple dye, with an optimal absorption at 595 nm. The reaction buffer was Tris-HCL 0.05 M with calcium chloride 5 mg/dl, pH 7. Enzymes concentrations in a 50 ml reaction buffer were as follows: Phospholipase D 6000U (added at the time of measurement), Choline oxidase 25U, Peroxidase 100OU. DAOS concentration was O.73mM and 4- aminoantipyrine concentration was 0.73 mM. Five μl of plasma were added to 100 μl reaction buffer plus enzymes and after 45 minutes incubation at 37 0C, the absorption was measured at 595 nm. Standard SM solution (100 mg/dl) preparation: 10 mg of PC was dissolved in 10 ml 2% Triton X-100 ethanol solution.
Total phospholipids measurement: The total choline-containing phospholipids (PC + SM) in plasma was measured by an enzymatic method (Wako Pure Chemical)
RESULTS
Enzymatic measurement of plasma SM or PC levels were carried out by using novel 4- or 3 -step procedure (Fig.l). As indicated in Fig 2, the linear range for the SM measurement was 0.5 to 5 μg and for PC was 2.5 to 20 μg (Fig.2). SM and PC concentration were measured in different amount of pooled plasma and found that the linear range for both assays was 2.5 μl to 10 μl (Fig.3).
Since both methods are very similar except the first step (Fig.l), it is likely that both measurements would interfere with each other. To investigate the specificity for the SM method, standard PC as a substrate or vice versa, and there was no crossing measurement in both methods (Fig.4 A and 4B).
Hemolysis is always occurred during the blood collecting. Since plasma SM concentration is significantly lower than cholesterol and PC, the hemolytic plasma may significantly interfere with the absorption reading of the assay. To investigate this effect, 10 μl of low, medium and high hemolytic plasma samples was utilized and incubated with SM assay solution but without SMase at 37 0C for 45 min, and their absorption was measured at 595 nm. It was found that that hemolysis did not interfere with SM assay (Fig.5). Reproducibility of methods: SM and PC were measured in one sample 20 times. The interassay coefficient of variation of the SM assay was 1.7+0.05% and PC assay was 3.1±0.13%.
To validate the novel SM and PC assays, total choline-containing phosphlipid (SM + PC) levels in mouse plasma was measured using a commercial available kit (Wako Pure Chemical), and these results were compared with the results obtained by adding SM and PC concentrations measured by the inventive methods.. It was found that the two approaches were correlated well (r=0.91, n=7) (Fig.6). Moreover, mouse plasma SM concentration was 38+10 mg/dl and PC was 150+21 mg/dl, PC/SM ratio was 3.9 (Table 1 ). All these results were comparable with those obtained by the classical methods (7).
Table 1. Comparison of the new methods for plasma SM and PC measurements with a commercial available kit which measuring total choline-containing phospholipids (PC + SM).
SM*(mg/dl) PC*(mg/dl) PC+SM (mg/dl) PC/SM PL**(mg/dL)
38±10 150±31 189±29 3.9±1.0 201+37
*Measured by the new methods. **Measured by a commercial Kit (Wako Pure Chemical). SM, sphingomyelin; PC, phosphatidylcholine. Values are mean + SD, n=17.
Modification of the SM measurement method: In order to increase the sensitivity of the SM measurement method as well as to avoid the effect of hemolysis, DAOS was instead of phenol in the last step of the reaction with the highest absorption at 595 nm. This change not only increases the sensitivity of the method (less than 10 mg/dl of SM can be detected) but also avoids the effect of hemolysis.
Standard curve for the SM and PC measurements: Standard curve with the standard SM (0.35 to 3.5 μg) was linear for the SM measurement method. Standard curve with the standard PC (6 to 24 μg) was linear for the PC measurement method. The linear range of plasma SM in the assay was between 10 and 120 mg/dl. The linear range of plasma PC in the assay was between 10 and 250 mg/dl.
Reproducibility of Methods: Using the new methods, SM and PC was measured in one sample 20 times. The interassay coefficient of variation of the SM assay was 1.7+0.05%. The interassay coefficient of variation of tήe PC assay was 3.1+0.13%. BRIEF DESCRIPTION OF THE FIGURES
Fig. 1. Strategy for SM and PC measurements. A. SMase catalyzes hydrolysis of SM to phosphorylcholine, alkaline phosphatase catalyzes in the second step in which P-choline produces choline. Oxidation of choline is the next step that catalyzes by choline oxidase. This reaction produces two hydrogen peroxides. The last step catalyzes by peroxidase, which produces a purple to blue dye that can be measured. B. Phospholipase D catalyzes the hydrolysis of PC to choline and phosphatidic acid. The rest of the reactions are similar to the SM measurement. Fig. 2. Standard curve for the SM and PC measurements. Different amount of SM or PC standard solution supplemented with saline to 20 μl was incubated with 100 μl of reaction buffer at 37 0C for 45 min, the absorption was measured at 595 nm. A. Standard curve for SM .B. Standard curve for PC.
Fig. 3. Linear range of plasma SM and PC measurements. Pooled mouse plasma was used. Different amount of the plasma supplemented with saline to 20 μl was incubated with 100 μl of reaction buffer at 37 0C for 45 min, the absorption was measured at 595 nm. A. Plasma linear range for SM measurement .B. Plasma linear range for PC measurement.
Fig. 4. Specificity of the SM and PC measurements. A. Different concentration of PC was used in the SM method; B. Different concentration of SM was used in the PC method.
Fig. 5. The effect of hemolysis on OD reading at 595 nm. Ten μl of low, medium and high hemolytic plasma samples are incubated with 100 μl of SM assay solution but without SMase at 37 0C for 45 min, and their absorption was measured at 595 nm. BKG: Background; LOW: Low hemolysis; MED: Medium hemolysis;
HIGH: High hemolysis.
Fig. 6. Comparison of the new methods for plasma SM and PC measurements with a commercial available kit (Wako) which measuring total choline-containing phospholipid. r=0.91, n=17.

Claims

WHAT IS CLAIMED IS:
1. A method for measuring plasma and tissue sphingomyelin and phosphatidylcholine comprising 1) catalyzing the hydrolysis of sphingomyelin to phosphorylcholine and n-acylsphingosine with bacterial SMase; 2) generating choline from phosphorylcholine produced from step 1) with alkaline phosphatase; 3) generating hydrogen peroxide by adding choline oxidase; and 4) adding hydrogen peroxide and with DAOS (N-Ethyl-N-(2-hydroxy-3~sulfopropyl)-3,5- dimethoxyaniline, sodium salt), 4-aminoantipyrine and peroxidase, to generate a blue to purple dye.
2. A method for measuring plasma and tissue sphingomyelin and phosphatidylcholine comprising 1) catalyzing the hydrolysis of phosphatidlycholine to choline and phosphatidic acid with bacterial phospholipase D; 2) generating hydrogen peroxide by adding choline oxidase; and 3) adding hydrogen peroxide and with DAOS (N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5- dimethoxyaniline, sodium salt), 4-aminoantipyrine and peroxidase, to generate a blue to purple dye.
3. The method according to claim 1, further comprising catalyzing the hydrolysis of phosphatidlycholine to choline and phosphatidic acid with bacterial phospholipase D in step 1.
PCT/US2006/047652 2005-12-15 2006-12-13 Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine WO2007078806A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP06847636A EP1960534A4 (en) 2005-12-15 2006-12-13 Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine
JP2008545793A JP2009519713A (en) 2005-12-15 2006-12-13 Enzymatic determination of sphingoemilin and phosphatidylcholine in plasma and tissue
AU2006333135A AU2006333135A1 (en) 2005-12-15 2006-12-13 Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine
US12/097,380 US20090148877A1 (en) 2005-12-15 2006-12-13 Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine
CA002634042A CA2634042A1 (en) 2005-12-15 2006-12-13 Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75062905P 2005-12-15 2005-12-15
US60/750,629 2005-12-15

Publications (2)

Publication Number Publication Date
WO2007078806A2 true WO2007078806A2 (en) 2007-07-12
WO2007078806A3 WO2007078806A3 (en) 2008-08-14

Family

ID=38228741

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/047652 WO2007078806A2 (en) 2005-12-15 2006-12-13 Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine

Country Status (8)

Country Link
US (1) US20090148877A1 (en)
EP (1) EP1960534A4 (en)
JP (1) JP2009519713A (en)
KR (1) KR20080082984A (en)
CN (1) CN101356283A (en)
AU (1) AU2006333135A1 (en)
CA (1) CA2634042A1 (en)
WO (1) WO2007078806A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308954A1 (en) * 2008-06-20 2011-04-13 Umeda Jimusho Ltd. Method for production of highly pure phospholipid, and highly pure sphingomyelin and plasmalogen-type glycerophospholipid produced by the method
WO2012070617A1 (en) * 2010-11-26 2012-05-31 国立大学法人滋賀医科大学 Phosphatidylserine quantification method and quantification kit
US8349319B2 (en) 2009-08-28 2013-01-08 Mount Sinai School Of Medicine Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
WO2014197859A1 (en) 2013-06-07 2014-12-11 Genzyme Corporation Marker for acid sphingomyelinase disorders and uses thereof
US9051600B2 (en) 2011-07-29 2015-06-09 Kyowa Medex Co., Ltd. Sphingomyelin measurement method using sequential phospholipase D reactions

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6315880B2 (en) * 2012-06-11 2018-04-25 国立大学法人滋賀医科大学 Sphingomyelin quantification method and quantification kit
US20170010290A1 (en) * 2015-07-07 2017-01-12 Mohmed E. Ashmaig Methods of determining a high density lipoprotein phospholipid level in a sample
CN106404683A (en) * 2015-07-27 2017-02-15 山东博科生物产业有限公司 Stable and strong anti-interference phospholipid detection reagent and detection method thereof
CN105543336B (en) * 2015-12-22 2019-03-12 山东博科生物产业有限公司 A kind of stabilization, the serum phospholipids detection reagent of strong antijamming capability and detection method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008205A (en) * 1997-04-04 1999-12-28 The Brigham & Women's Hospital, Inc. Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses
US6248553B1 (en) * 1998-10-22 2001-06-19 Atairgin Technologies, Inc. Enzyme method for detecting lysophospholipids and phospholipids and for detecting and correlating conditions associated with altered levels of lysophospholipids
JP4070958B2 (en) * 1999-04-01 2008-04-02 正彦 岡田 Triglyceride determination method for ultra-low density lipoprotein and intermediate density lipoprotein
AU2001255477A1 (en) * 2000-04-19 2001-11-07 The Trustees Of Columbia University In The City Of New York Detection and treatment of atherosclerosis based on plasma sphingomyelin concentration

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1960534A4 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524282B2 (en) 2008-06-20 2013-09-03 Umeda Jimusho Ltd. Method for production of highly pure phospholipid, and highly pure sphingomyelin and plasmalogen-type glycerophospholipid produced by the method
EP2308954A4 (en) * 2008-06-20 2011-09-21 Umeda Jimusho Ltd Method for production of highly pure phospholipid, and highly pure sphingomyelin and plasmalogen-type glycerophospholipid produced by the method
EP2308954A1 (en) * 2008-06-20 2011-04-13 Umeda Jimusho Ltd. Method for production of highly pure phospholipid, and highly pure sphingomyelin and plasmalogen-type glycerophospholipid produced by the method
US10188705B2 (en) 2009-08-28 2019-01-29 Icahn School Of Medicine At Mount Sinai Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
EP3482767A1 (en) 2009-08-28 2019-05-15 Icahn School of Medicine at Mount Sinai Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
US8658162B2 (en) 2009-08-28 2014-02-25 Icahn School Of Medicine At Mount Sinai Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
US8709408B2 (en) 2009-08-28 2014-04-29 Icahn School Of Medicine At Mount Sinai Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
EP3998078A1 (en) 2009-08-28 2022-05-18 Icahn School of Medicine at Mount Sinai Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
US8349319B2 (en) 2009-08-28 2013-01-08 Mount Sinai School Of Medicine Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
US9114139B2 (en) 2009-08-28 2015-08-25 Icahn School Of Medicine At Mount Sinai Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
US9655954B2 (en) 2009-08-28 2017-05-23 Icahn School Of Medicine At Mount Sinai Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
WO2012070617A1 (en) * 2010-11-26 2012-05-31 国立大学法人滋賀医科大学 Phosphatidylserine quantification method and quantification kit
US9051600B2 (en) 2011-07-29 2015-06-09 Kyowa Medex Co., Ltd. Sphingomyelin measurement method using sequential phospholipase D reactions
US10022428B2 (en) 2013-06-07 2018-07-17 Genzyme Corporation Marker for acid sphingomyelinase disorders and uses thereof
EP3584580A1 (en) 2013-06-07 2019-12-25 Genzyme Corporation Recombinant human acid sphingomyelinase for use in treating human asmd
US10888607B2 (en) 2013-06-07 2021-01-12 Genzyme Corporation Marker for acid sphingomyelinase disorders and uses thereof
WO2014197859A1 (en) 2013-06-07 2014-12-11 Genzyme Corporation Marker for acid sphingomyelinase disorders and uses thereof
US11998592B2 (en) 2013-06-07 2024-06-04 Genzyme Corporation Methods of treating acid sphingomyelinase deficiency

Also Published As

Publication number Publication date
AU2006333135A1 (en) 2007-07-12
CA2634042A1 (en) 2007-07-12
US20090148877A1 (en) 2009-06-11
EP1960534A4 (en) 2009-03-25
KR20080082984A (en) 2008-09-12
EP1960534A2 (en) 2008-08-27
CN101356283A (en) 2009-01-28
WO2007078806A3 (en) 2008-08-14
JP2009519713A (en) 2009-05-21

Similar Documents

Publication Publication Date Title
US20090148877A1 (en) Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine
Luria et al. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice
Hojjati et al. Rapid, specific, and sensitive measurements of plasma sphingomyelin and phosphatidylcholine
JP4472872B2 (en) Enzymatic methods for measuring lysophospholipids and phospholipids and their association with disease
CN103952462B (en) The method and kit of quantification of small, dense LDL cholesterol
EP1813680A1 (en) Compositions for lipase activity determination and method of determining activity
He et al. A fluorescence-based, high-throughput sphingomyelin assay for the analysis of Niemann–Pick disease and other disorders of sphingomyelin metabolism
EP3779456A1 (en) Quantification method, quantification reagent and quantification kit for lipoprotein cholesterol
US8361732B2 (en) Combination of sPLA2 activity and oxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
Morita et al. Enzymatic measurement of phosphatidic acid in cultured cells
EP2483682A1 (en) Combination of spla2 activity and lp(a) cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
KR20130043184A (en) Method for quantifying the amount of cholesterol in high-density lipoprotein 3
EP2639310B1 (en) Method for quantification of remnant-like lipoprotein cholesterol and kit for same
CN101065495B (en) Method of measuring cholesterol in remnant-like lipoproteins
TWI731088B (en) Method of quantifying cholesterol in triglyceride-rich lipoprotein
US20030017523A1 (en) Method of measuring lipid components and method of examining of renal failure
KR20130043185A (en) Method for quantifying the amount of cholesterol in high-density lipoprotein 3
KR101871209B1 (en) Method for quantifying cholesterol in high-density lipoprotein 2, and reagent kit for the method
Zhang et al. Comprehensive evaluation of genetic and environmental factors influencing the plasma lipoprotein-associated phospholipase A2 activity in a Japanese population
US20160145672A1 (en) Paraoxonase 1 enzymatic activity, a risk predictor for major adverse cardiovascular events
US6448023B1 (en) Enzyme method for detecting sphingosine-1-phosphate (S1P)
Kimura et al. An enzyme combination assay for serum sphingomyelin: Improved specificity through avoiding the interference with lysophosphatidylcholine
JP2002017398A (en) Method of measuring lysophospholipid

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680046632.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008545793

Country of ref document: JP

Ref document number: 5085/DELNP/2008

Country of ref document: IN

Ref document number: 2634042

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006333135

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006847636

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006333135

Country of ref document: AU

Date of ref document: 20061213

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087017077

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 12097380

Country of ref document: US